Small-scale, semi-automated purification of eukaryotic proteins for structure determination

The University of Wisconsin Center for Eukaryotic Structural Genomics and Department of Biochemistry, University of Wisconsin, Room 141B, 433 Babcock Drive, Madison, WI 53706, USA.
Journal of Structural and Functional Genomics 01/2008; 8(4):153-66. DOI: 10.1007/s10969-007-9032-5
Source: PubMed

ABSTRACT A simple approach that allows cost-effective automated purification of recombinant proteins in levels sufficient for functional characterization or structural studies is described. Studies with four human stem cell proteins, an engineered version of green fluorescent protein, and other proteins are included. The method combines an expression vector (pVP62K) that provides in vivo cleavage of an initial fusion protein, a factorial designed auto-induction medium that improves the performance of small-scale production, and rapid, automated metal affinity purification of His8-tagged proteins. For initial small-scale production screening, single colony transformants were grown overnight in 0.4 ml of auto-induction medium, produced proteins were purified using the Promega Maxwell 16, and purification results were analyzed by Caliper LC90 capillary electrophoresis. The yield of purified [U-15N]-His8-Tcl-1 was 7.5 microg/ml of culture medium, of purified [U-15N]-His8-GFP was 68 microg/ml, and of purified selenomethione-labeled AIA-GFP (His8 removed by treatment with TEV protease) was 172 microg/ml. The yield information obtained from a successful automated purification from 0.4 ml was used to inform the decision to scale-up for a second meso-scale (10-50 ml) cell growth and automated purification. 1H-15N NMR HSQC spectra of His8-Tcl-1 and of His8-GFP prepared from 50 ml cultures showed excellent chemical shift dispersion, consistent with well folded states in solution suitable for structure determination. Moreover, AIA-GFP obtained by proteolytic removal of the His8 tag was subjected to crystallization screening, and yielded crystals under several conditions. Single crystals were subsequently produced and optimized by the hanging drop method. The structure was solved by molecular replacement at a resolution of 1.7 A. This approach provides an efficient way to carry out several key target screening steps that are essential for successful operation of proteomics pipelines with eukaryotic proteins: examination of total expression, determination of proteolysis of fusion tags, quantification of the yield of purified protein, and suitability for structure determination.

Download full-text


Available from: David J Aceti, Jul 01, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A nitrile hydratase (NHase) gene from Aurantimonas manganoxydans was cloned and expressed in Escherichia coli BL21 (DE3). A downstream gene adjacent to the β-subunit was necessary for the functional expression of the recombinant NHase. The structural gene order of the Co-type NHase was α-subunit beyond β-subunit, different from the order typically reported for Co-type NHase genes. The NHase exhibited adequate thermal stability, with a half-life of 1.5 h at 50 °C. The NHase efficiently hydrated 3-cyanopyridine to produce nicotinamide. In a 1-L reaction mixture, 3.6 mol of 3-cyanopyridine was completely converted to nicotinamide in four feedings, exhibiting a productivity of 187 g nicotinamide/g dry cell weight/h. An industrial auto-induction medium was applied to produce the recombinant NHase in 10-L fermenter. A glycerol-limited feeding method was performed, and a final activity of 2170 U/mL culture was achieved. These results suggested that the recombinant NHase was efficiently cloned and produced in E. coli.
    PROCESS BIOCHEMISTRY 12/2013; 48(12):1921–1927. DOI:10.1016/j.procbio.2013.09.004 · 2.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: CESG's strategy to minimize costs and maximize the output of soluble proteins suitable for purification uses small-scale screening methodologies to identify proteins targets that are statistically likely to proceed through all downstream processing stages (large-scale protein production and generic IMAC purification). Passage through the entire cell-based protein production process, beginning with gene cloning, requires ~2-3 months to deliver ~10 mg of purified, isotopically enriched protein for either NMR spectroscopy screens or X-ray crystallization trials. Small-scale screening identifies several important features of cloned eukaryotic proteins that together indicate whether the proteins will be "suitable" for structural studies. CESG small-scale methodologies include expression vector engineering, optimization and improvement of auto-induction medium using factorial evolution techniques, and automated protein production analysis. These approaches have been used to identify the best eukaryotic proteins (Arabidopsis, rice, human, yeast, zebrafish, mouse, and algae) for large-scale cell growths (2 liter), and also yield sufficient sample for functional studies and preliminary structural analysis. The CESG cell-based small-scale methodologies have proven to be rapid, simple, efficient, and cost-effective. The approaches developed provide information on the level of expression, the potential for in vivo degradation; the solubility of the MBP fusion; the ability of TEV protease to cleave the fusion, and the yield of cleaved and purified target protein.The small-scale screening method is flexible and assessments of the above mentioned properties are made prior to committing valuable resources for downstream processes. Over a 2 year period, this approach has successfully predicted proteins that are suitable for large-scale production and purification with ~80% accuracy. In summary, the CESG small-scale purification screening approach saves considerable resources and labor, and reduces expenditure of resources on proteins targets that will ultimately fail in protein purification.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Figure 1 shows the success rates of various stages in the CESG pipeline. At the small-scale screen, 53% of the eukaryotic proteins are tested and shown to be suitable for large-scale cell growths. These targets are screened and shown to be highly expressed, soluble and cleaved by TEV protease. About 47% of the proteins screened are unsuitable for scale-up, due to weak expression (accounts for ~36% of total targets), and 11% of targets are expressed but have low solubility. Abstract CESG performs research and development dedicated to providing eukaryotic targets for structure determination by NMR spectroscopy and X-ray crystallography. Our extensive small-scale screening shows that 36% of all eukaryotic proteins are unsuitable for scale-up due to no expression and 11% are unsuitable because of low solubility. The remaining 53% of target proteins are expressed, soluble and cleaved by TEV protease, and historically deemed suitable for scale-up. However, of this 53%, ~2/3 were eventually lost during purification for various reasons that will be reported. In order to address these different modes for loss of valuable protein targets, CESG is exploring several strategies and approaches, and wheat germ cell-free translation has been one effective way to increase the number of protein targets recovered. In a cell- based approach, the modular CESG expression vector platform has been exploited to replace the MBP solubility tag with alternative solubility tags such as thioredoxin, trigger factor, and others. Research with these alternative tags is facilitated by side-by-side comparison with results obtained from CESG control workgroups composed of proteins markers for efficient function of each step in the protein production process. In another cell-based approach, CESG bioinformatics and cloning methods were used to generate N- and C-terminal deletions of target proteins to improve their behavior. This approach has given new insight into the 3-dimensional structure of mammalian metallo-chaperones. The effectiveness of the domain engineering methods can be extended when coupled with the Promega Maxwell 16 Automation System to rapidly isolate and characterize purified proteins at the small-scale, and is often informed by evaluation of 15N HSQC spectra. Small-scale purification screening is also facilitated when coupled to bacterial expression in factorial evolved auto- induction medium, which can yield expressed protein levels as high as 1.5 mg/ mL of culture fluid. In another approach, different affinity purification methods are being applied to recover proteins with intact cofactors and metal-binding sites. This approach has successfully yielded mouse and human Rieske-type ferredoxins, a novel fold not previously associated with higher eukaryotes. Other examples based on innovation of our established research methods for eukaryotic protein production will be presented. PURIFICATION One possible explanation for weak protein production in unsuitable target proteins may be that their mRNA is degraded rapidly before translation is completed. We tested this hypothesis by using E. coli strains that give improved mRNA stability. Figure 2 shows the effect on protein production and suitability ratings of using BL21-Star, which that has reduced mRNA degradation activity due to a mutation in RNase E (rne 131), that reduces mRNA degradation (Figure 2). In this strain, 7 new targets were expressed, possibly implicating mRNA stability. However, all of these new proteins expressed in BL21-Star were insoluble or uncleaved by TEV protease. Our findings show that even though a minority of protein for a test set were newly produced, none had solubility or TEV cleavage properties that are also needed to achieve a "suitable" rating. In conclusion, using host strains with improved mRNA stability did not help recover unsuitable targets that failed the initial CESG pipeline screening using B834-pRARE2. These findings suggest that other strategies have to be explored to recover unsuitables with weak expression and solubility. The modular design strategy of the CESG vectors used for protein production (Figure 3) allows this ease in design modification and testing for incremental improvements. We are now using this flexibility to test alternative protein production approaches and salvage pathways Expressed B834-pRARE2 (Pipeline)